December 27th, 2016
•Biofilm infections show high tolerance towards chemotherapy. No single assay captures the complexity of biofilms. Instead, complementary assays are needed. We present a screening platform (developed for S. aureus) that combines assays for viability, biomass, and biofilm matrix. It allows anti-biofilm drug discovery, including the assessment of long-term chemotherapeutic effects.
Related Videos
Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials
Flow Cytometric Analysis of Natural Killer Cell Lytic Activity in Human Whole Blood
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
Combining Analysis of DNA in a Crude Virion Extraction with the Analysis of RNA from Infected Leaves to Discover New Virus Genomes
A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved